StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the stock.
Separately, Alliance Global Partners reduced their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating on the stock in a research report on Wednesday, August 14th.
Check Out Our Latest Report on AWH
Aspira Women’s Health Stock Up 6.8 %
Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same quarter in the prior year, the company earned ($0.28) earnings per share. On average, research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.
Institutional Trading of Aspira Women’s Health
A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 43.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.
About Aspira Women’s Health
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
See Also
- Five stocks we like better than Aspira Women’s Health
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What is a Death Cross in Stocks?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Using the MarketBeat Dividend Tax Calculator
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.